Medtronic Plc (MDT) shines in the spotlight as it makes significant strides with new appointments, solid financial reports, strategic shifts, and dividends. A notable appointment is
Dr. Joon Sup Lee, who brings expertise from his years of service in the $7.7B Healthcare System. In company financials, Medtronic has consistently proven to be a strong player demonstrating promising Q3 and Q4 results for the fiscal year 2025.
Jim Cramer endorses the company's potential, labeling Medtronic as a 'Medical Device Powerhouse' and its future being 'AI-Powered'. Furthermore, in a strategic move, Medtronic announced its intent to
separate its Diabetes business, revealing
MiniMed as the standalone entity. Despite a drop in share prices during these developments, Medtronic has had eight consecutive sessions of share price upticks. The company's steady financial performance, expanding board, and strategic decisions, combined with endorsements from industry experts, all point to a promising future. Medtronic has also been flagged as one of the best high-yield dividend stocks for 2025 and beyond, offering an attractive investment opportunity.
Medtronic Plc MDT News Analytics from Tue, 05 Nov 2024 08:00:00 GMT to Sat, 28 Jun 2025 16:41:25 GMT -
Rating 8
- Innovation 7
- Information 9
- Rumor -3
